基于模型给药抗胸腺细胞球蛋白改善儿童造血细胞移植生存
报告单臂2期PARACHUTE试验及真实世界经验,评估基于模型精准给药抗胸腺细胞球蛋白(MBD-ATG)在儿童首次T细胞充足造血细胞移植中的效果,并与历史固定剂量(FIX-ATG)患者比较。MBD-ATG组214例(试验58例,真实世界156例),FIX-ATG组100例。MBD-ATG组总生存优于FIX-ATG(死亡HR 0.56,95%CI 0.34-0.93,P=0.026),治疗相关死亡率更低(HR 0.51,95%CI 0.29-0.92,P=0.025),T细胞重建成功率更高(87%±2% vs 47%±5%,P<0.0001),慢性GVHD和植入失败更少,2-4级急性GVHD相当。
要点
- MBD-ATG较FIX-ATG改善总生存(死亡HR 0.56,95%CI 0.34-0.93,P=0.026)并降低治疗相关死亡率(HR 0.51,95%CI 0.29-0.92,P=0.025)。
- MBD-ATG组T细胞重建成功率87%±2% vs FIX-ATG组47%±5%(P<0.0001),T细胞重建改善与治疗相关死亡率降低相关(HR 0.19,95%CI 0.09-0.36,P<0.0001)。
- MBD-ATG组慢性GVHD(HR 0.35,95%CI 0.17-0.72,P=0.004)和植入失败(HR 0.36,95%CI 0.13-0.97,P=0.044)均少于FIX-ATG组,2-4级急性GVHD发生率相当。
核心结论
- MBD-ATG可改善儿童造血细胞移植后的总生存并降低治疗相关死亡率,同时减少慢性GVHD和植入失败。
- 作者认为这种易于实施的方法改善了儿童造血细胞移植的结局,但需要验证性研究。
研究设计与样本
- 报告单臂2期PARACHUTE试验的更新结果,并结合使用相同MBD-ATG的真实世界经验。
- 连续纳入因任何适应症接受首次T细胞充足造血细胞移植的患者,并与接受传统固定剂量ATG(FIX-ATG)的历史患者比较。
- MBD-ATG组214例(试验患者58例,真实世界患者156例);FIX-ATG组100例。
- 主要结局为总生存。
- PARACHUTE试验在荷兰试验注册中心注册,注册号为#NL4836。
主要发现
- MBD-ATG组总生存优于FIX-ATG组(死亡HR 0.56,95%CI 0.34-0.93,P=0.026)。
- MBD-ATG组治疗相关死亡率低于FIX-ATG组(HR 0.51,95%CI 0.29-0.92,P=0.025)。
- MBD-ATG组T细胞重建成功率高于FIX-ATG组(87%±2% vs 47%±5%,P<0.0001);定义为移植后100天内两次CD4+ T细胞>0.05×10^9/L。
- T细胞重建改善与治疗相关死亡率降低相关(HR 0.19,95%CI 0.09-0.36,P<0.0001)。
- MBD-ATG组较FIX-ATG组慢性GVHD更少(HR 0.35,95%CI 0.17-0.72,P=0.004),植入失败更少(HR 0.36,95%CI 0.13-0.97,P=0.044);2-4级急性GVHD发生率相当。
局限性
- 原文结论指出需要验证性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antithymocyte globulin (ATG) is used in pediatric allogeneic hematopoietic cell transplantation (HCT) to prevent graft-versus-host disease (GVHD) and graft failure (GF). Poor T-cell recovery, associated with increased mortality, is the main toxicity of ATG. Model-based precision dosing of ATG (MBD-ATG) minimizes toxicity while maintaining efficacy. We report updated results of the single-arm phase 2 PARACHUTE trial investigating MBD-ATG, combined with real-world experience using identical MBD-ATG. Consecutive patients receiving a first T-cell-replete HCT for any indication were evaluated. Results were compared with historical patients receiving conventional fixed ATG dosing (FIX-ATG). Primary outcome was overall survival (OS). The MBD-ATG group consisted of 214 patients (58 trial patients; 156 real-world patients); 100 patients received FIX-ATG. MBD-ATG led to superior OS compared with FIX-ATG (hazard ratio [HR] for death, 0.56; 95% confidence interval [CI], 0.34-0.93; P = .026), and lower treatment-related mortality (TRM; HR, 0.51; 95% CI, 0.29-0.92; P = .025). Successful T-cell reconstitution (>0.05 × 109/L CD4+ T cells twice within 100 after HCT) was improved in MBD-ATG vs FIX-ATG (87% ± 2% vs 47% ± 5%; P < .0001). The improved T-cell reconstitution led to lower TRM (HR, 0.19; 95% CI, 0.09-0.36; P < .0001). Incidence of grade 2-4 acute GVHD was comparable, whereas chronic GVHD (HR, 0.35; 95% CI, 0.17-0.72; P = .004) and GF (HR, 0.36; 95% CI, 0.13-0.97; P = .044) were both less frequent in MBD-ATG compared with FIX-ATG. MBD-ATG results in improved OS and reduced TRM, while reducing chronic GVHD and GF. This easy-to-implement approach improves outcomes after pediatric HCT, confirmatory studies are needed. The PARACHUTE trial is registered with the Dutch Trial Register as #NL4836.
引用
- Admiraal R, Nierkens S, Bierings MB, et al. Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation. Blood Adv. 2025. PMID: 39983052. doi:10.1182/bloodadvances.2024014836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。